bpc 157 fda Exciting news for peptides coming out of today's committee hearing! The Pharmacy Compounding Advisory Committee voted 8-6 to recommend adding BPC- to the 503A Bulks List for use in compounding for FDA's own advisory committee voted
FDA's own advisory committee voted 8 6 Thursday. BPC 157, on the compounding list now, for ulcerative colitis. FDA staff argued against it, laid out the data gaps, the whole case. Panel overruled them FDA is reviewing seven peptides this week, BPC 157, MOTS c, and Epitalon among them. Committee meets Thursday and Friday, and the likely outcome is tighter restrictions on compounding pharmacies. Read past the headline Repost @peptides with @use.repost BREAKING NEWS! Today's 86 advisory vote for BPC 157 is one of the biggest peptide regulatory developments we've seen in years. While nothing changes immediately, the recommendation represents Most FDA advisers say peptides like BPC 157 and TB 500 should be made available in the U.S. Here's what happens next. MarketWatch
Pay in 4 interest-free payments of $5.22 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 30 - Aug 4